XLV Trails S&P 500 for a Decade, 2 Factors Could Close Gap in 2026
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
XLVhealthcare-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
The Health Care Select Sector SPDR ETF (XLV) has underperformed the S&P 500 by an annualized 220 basis points over the past ten years. Analysis of forward catalysts suggests 2026 could be the year this persistent gap closes, driven by regulatory clarity on drug pricing and the expanding commercial impact of weight-loss drugs. Finance.yahoo.com reported on June 21, 2026, that these two factors are critical for XLV to finally catch up to the broader market's returns this year.
Healthcare has been a persistent underperformer in the post-pandemic era. The last time XLV meaningfully outperformed the S&P 500 for a full calendar year was in 2022, when it beat the index by 730 basis points due to post-COVID normalization. Since then, the sector has faced headwinds from patent cliffs, regulatory uncertainty, and a higher interest rate environment that pressured growth stock valuations.
The current macro backdrop features a Federal Reserve holding rates steady in a 4.25-4.50% range, which historically pressures high-multiple growth sectors. The trigger for a potential 2026 reversal is twofold. First, final rules for the Medicare drug price negotiation program under the Inflation Reduction Act are due by September 30, 2026, removing a key overhang. Second, the revenue contribution from GLP-1 agonists for obesity and cardiometabolic diseases is projected to exceed $120 billion globally, providing a substantial earnings tailwind for select constituents.
XLV's ten-year annualized return stands at 8.1%, compared to the S&P 500's 10.3%. The fund holds 64 stocks with a combined market capitalization of $8.7 trillion. Eli Lilly (LLY) and UnitedHealth Group (UNH) are its top holdings, comprising 22.5% of the portfolio weight. The ETF's price-to-earnings ratio of 18.3 trades at a 12% discount to the S&P 500's 20.8 multiple.
Performance metrics for the trailing five years show the depth of the divergence:
| Period | XLV Return | S&P 500 Return | Performance Gap |
|---|---|---|---|
| 1-Year | +14.2% | +16.8% | -260 bps |
| 3-Year | +7.1% | +9.5% | -240 bps |
| 5-Year | +9.8% | +12.1% | -230 bps |
The sector’s performance disparity is not uniform. While managed care and providers have struggled, biotechnology has shown pockets of strength, with the SPDR S&P Biotech ETF (XBI) up 22% year-to-date versus XLV's 14.2% gain.
A catch-up trade in XLV would generate significant second-order effects across subsectors. Large-cap pharmaceutical names like Merck (MRK) and Bristol-Myers Squibb (BMY), which have borne the brunt of drug pricing fears, could see multiple expansion of 1-2 turns if regulatory fears abate. Medical device companies, including Medtronic (MDT) and Boston Scientific (BSX), would benefit from procedural volume stability and less exposure to weight-loss drug displacement narratives.
A key counter-argument is that GLP-1 revenue is highly concentrated, primarily benefiting Eli Lilly and Novo Nordisk. If other portfolio companies cannot demonstrate offsetting growth, XLV's performance may remain top-heavy and volatile. Institutional positioning data from the CFTC shows asset managers have been increasing net long exposure to healthcare sector futures for three consecutive months, with particular flow into biotech and pharmaceutical names, while reducing exposure to managed care.
Investors should monitor two specific catalysts with firm deadlines. The Centers for Medicare & Medicaid Services (CMS) will announce the final list of the next ten drugs selected for price negotiation by September 1, 2026. Second, Q3 2026 earnings reports from Eli Lilly and Novo Nordisk, starting in late October, will provide concrete data on GLP-1 market expansion and prescription trends.
Key technical levels for XLV include a major resistance zone between $155 and $158, which represents the 2025 highs. A sustained breakout above this level on above-average volume would confirm a bullish structural shift. On the downside, the 200-day moving average near $142 acts as critical support. The relative strength ratio of XLV versus the SPDR S&P 500 ETF (SPY) must break above its two-year downtrend line for the convergence thesis to gain technical validation.
For retail investors, XLV converging with the S&P 500 would signal a major rotation into a defensive sector that has been out of favor. It could reduce portfolio volatility as healthcare stocks are less cyclical than technology or consumer discretionary names. A successful catch-up would also validate strategic sector allocation over simple index investing for the 2024-2026 period, highlighting the value of identifying turning points in long-term performance trends.
The current decade-long underperformance is unusually persistent. Prior periods of healthcare lag, such as 1999-2000 or 2007-2008, lasted 18-24 months and were followed by sharp recoveries. The current streak is more akin to the technology sector's 'lost decade' from 2000-2010. This extended duration increases the statistical probability of a mean-reversion event, as sector leadership rarely remains static beyond a full market cycle.
GLP-1 drugs are a net positive for XLV, but the benefit is uneven. While Eli Lilly and Novo Nordisk see direct revenue lifts, companies focused on diabetes complications, certain medical devices, and weight-management services face displacement risk. The net effect is positive because the revenue generated for the top holders outweighs losses elsewhere in the portfolio, and the innovation narrative attracts generalist investor capital back to the entire healthcare sector.
XLV’s path to parity with the S&P 500 in 2026 depends on resolving drug pricing uncertainty and broadening the economic benefits of GLP-1 drugs beyond two stocks.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.